Traws Pharma Q2 2024 GAAP EPS $(4.87), Sales $57.00K Down From $60.00K YoY
Portfolio Pulse from Benzinga Newsdesk
Traws Pharma (NASDAQ:TRAW) reported a Q2 2024 GAAP EPS loss of $(4.87) per share and sales of $57.00K, a 5% decrease from $60.00K YoY.

August 15, 2024 | 11:19 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Traws Pharma reported a significant quarterly loss of $(4.87) per share and a 5% decrease in sales YoY, indicating financial struggles.
The significant loss per share and the decrease in sales suggest that Traws Pharma is facing financial difficulties, which is likely to negatively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100